Suppr超能文献

评估质谱蛋白质检测设施用于鉴定多种人类肽的外部质量保证试验。

An external quality assurance trial to assess mass spectrometry protein testing facilities for identifying multiple human peptides.

机构信息

Royal College of Pathologists of Australasia Quality Assurance Programs, Molecular Genetics, 8 Herbert Street, St Leonard's, Sydney, NSW, 2065, Australia.

Future Industries Institute, Mawson Lakes Campus, University of South Australia, GPO Box 2471, Adelaide, SA, 5001, Australia.

出版信息

Anal Bioanal Chem. 2019 Oct;411(25):6575-6581. doi: 10.1007/s00216-019-02047-y. Epub 2019 Aug 5.

Abstract

The application of proteomic liquid chromatography mass spectrometry (LC-MS) for identifying proteins and peptides associated with human disease is rapidly growing in clinical diagnostics. However, the ability to accurately and consistently detect disease-associated peptides remains clinically uncertain. Variability in diagnostic testing occurs in part due to the absence of appropriate reference testing materials and standardised clinical guidelines for proteomic testing. In addition, multiple proteomic testing pipelines have not been fully assessed through external quality assurance (EQA). This trial was therefore devised to evaluate the performance of a small number of mass spectrometry (MS) testing facilities to (i) evaluate the EQA material for potential usage in a proteomic quality assurance program, and to (ii) identify key problem areas associated with human peptide testing. Five laboratories were sent six peptide reference testing samples formulated to contain a total of 35 peptides in differing ratios of light (natural) to heavy (labelled) peptides. Proficiency assessment of laboratory data used a modified approach to similarity and dissimilarity testing that was based on Bray-Curtis and Sorensen indices. Proficiency EQA concordant consensus values could not be derived from the assessed data since none of the laboratories correctly identified all reference testing peptides in all samples. However, the produced data may be reflective of specific inter-laboratory differences for detecting multiple peptides since no two testing pipelines used were the same for any laboratory. In addition, laboratory feedback indicated that peptide filtering of the reference material was a common key problem area prior to analysis. These data highlight the importance of an EQA programme for identifying underlying testing issues so that improvements can be made and confidence for clinical diagnostic analysis can be attained.

摘要

蛋白质组学液相色谱-质谱联用(LC-MS)在鉴定与人类疾病相关的蛋白质和肽方面的应用在临床诊断中迅速发展。然而,准确和一致地检测与疾病相关的肽的能力在临床上仍然不确定。诊断测试的可变性部分归因于缺乏适当的参考测试材料和标准化的蛋白质组学测试临床指南。此外,多个蛋白质组学测试管道尚未通过外部质量保证(EQA)进行全面评估。因此,进行了这项试验来评估少数几个质谱(MS)测试设施的性能,以 (i) 评估 EQA 材料是否有可能用于蛋白质质量保证计划,以及 (ii) 确定与人类肽测试相关的关键问题领域。向五个实验室发送了六个肽参考测试样本,这些样本配方中包含总共有 35 个肽,其中轻(天然)和重(标记)肽的比例不同。使用基于 Bray-Curtis 和 Sorensen 指数的相似性和相异性测试的修改方法对实验室数据进行了能力评估。由于没有一个实验室能够在所有样本中正确识别所有参考测试肽,因此无法从评估数据中得出专业 EQA 一致共识值。然而,所产生的数据可能反映了检测多个肽的特定实验室间差异,因为没有两个实验室使用相同的测试管道。此外,实验室反馈表明,在分析之前,对参考材料进行肽过滤是一个常见的关键问题领域。这些数据强调了 EQA 计划对于识别潜在测试问题的重要性,以便可以进行改进并获得临床诊断分析的信心。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验